Impact of 6 weeks of treatment with low-dose metformin and atorvastatin on glucose-induced changes of endothelial function in adults with newly diagnosed type 2 diabetes mellitus: A single-blind study.

[1]  Paul M. Ridker,et al.  Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis , 2009, Diabetes Care.

[2]  K. Channon,et al.  L-arginine and tetrahydrobiopterin protects against ischemia/reperfusion-induced endothelial dysfunction in patients with type 2 diabetes mellitus and coronary artery disease. , 2009, Atherosclerosis.

[3]  G. Moneta,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[4]  C. Nacci,et al.  Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. , 2009, Current medicinal chemistry.

[5]  Xiaomin Liu,et al.  Endothelial dysfunction in impaired fasting glycemia, impaired glucose tolerance, and type 2 diabetes mellitus. , 2008, The American journal of cardiology.

[6]  T. Zima,et al.  Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus , 2007, European Journal of Clinical Pharmacology.

[7]  I. Laher,et al.  Hyperglycemia and hyperlipidemia are associated with endothelial dysfunction during the development of type 2 diabetes. , 2007, Canadian Journal of Physiology and Pharmacology.

[8]  C. Tsioufis,et al.  Effects of Insulin Dependence on Inflammatory Process, Thrombotic Mechanisms and Endothelial Function, in Patients with Type 2 Diabetes Mellitus and Coronary Atherosclerosis , 2007, Clinical cardiology.

[9]  R. Vigersky,et al.  A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. , 2007, American heart journal.

[10]  Kunihiro Suzuki,et al.  Metformin Inhibits Cytokine-Induced Nuclear Factor &kgr;B Activation Via AMP-Activated Protein Kinase Activation in Vascular Endothelial Cells , 2006, Hypertension.

[11]  C. Tsioufis,et al.  The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level. , 2006, International journal of cardiology.

[12]  James L. Young,et al.  Metformin Inhibits Proinflammatory Responses and Nuclear Factor-&kgr;B in Human Vascular Wall Cells , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[13]  R. Urquhart,et al.  Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. , 2005, Diabetes research and clinical practice.

[14]  C. Stefanadis,et al.  Evaluating endothelial function in humans: a guide to invasive and non-invasive techniques , 2005, Heart.

[15]  A. Field.  Discovering statistics using SPSS : (and sex, drugs and rock'n' roll) , 2005 .

[16]  C. Stehouwer,et al.  Vascular complications in diabetes mellitus: the role of endothelial dysfunction. , 2005, Clinical science.

[17]  M. Kashyap,et al.  Pharmacologic Treatment of Type 2 Diabetic Dyslipidemia , 2004, Pharmacotherapy.

[18]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[19]  C. Tsioufis,et al.  Vascular endothelium and inflammatory process, in patients with combined Type 2 diabetes mellitus and coronary atherosclerosis: the effects of vitamin C , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[20]  E. Ferrannini,et al.  Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. , 2004, Diabetes care.

[21]  M. Bots,et al.  Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. , 2002, Diabetes care.

[22]  K. Lam,et al.  Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. , 2002, The Journal of clinical endocrinology and metabolism.

[23]  M. Huisman,et al.  Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. , 2001, Cardiovascular research.

[24]  C. de Ciuceis,et al.  Endothelial dysfunction in small resistance arteries of patients with non-insulin-dependent diabetes mellitus , 2001, Journal of hypertension.

[25]  K. Mather,et al.  Improved endothelial function with metformin in type 2 diabetes mellitus. , 2001, Journal of the American College of Cardiology.

[26]  J. Callés-Escandon,et al.  Diabetes and endothelial dysfunction: a clinical perspective. , 2001, Endocrine reviews.

[27]  D. Black,et al.  Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. , 2000, Atherosclerosis.

[28]  S. Haffner,et al.  Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. , 1999, Archives of internal medicine.

[29]  M. Velussi,et al.  Atorvastatin for the management of Type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience. , 1999, Diabetes, nutrition & metabolism.

[30]  J. Sowers,et al.  Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells. , 1998, Endocrinology.

[31]  L. Ragolia,et al.  Vascular smooth muscle cell growth and insulin regulation of mitogen-activated protein kinase in hypertension. , 1998, The American journal of physiology.

[32]  U. Laufs,et al.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.

[33]  U. Laufs,et al.  Inhibition of 3-Hydroxy-3-methylglutaryl (HMG)-CoA Reductase Blocks Hypoxia-mediated Down-regulation of Endothelial Nitric Oxide Synthase* , 1997, The Journal of Biological Chemistry.

[34]  A. Yeung,et al.  The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. , 1995, The New England journal of medicine.

[35]  W. Weintraub,et al.  Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. , 1995, The New England journal of medicine.

[36]  M. Sugimachi,et al.  Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. , 1994, Circulation.

[37]  R. Krauss,et al.  Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. , 1993, The Journal of clinical investigation.

[38]  D. Cox,et al.  Evaluating Clinical Accuracy of Systems for Self-Monitoring of Blood Glucose , 1987, Diabetes Care.

[39]  Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. , 1979, Diabetes.